Sanofi fell 9.3 percent. The company's experimental stroke drug Idraparinux caused more bleeding in some patients than a standard treatment in a study stopped ahead of schedule in 2005, researchers writing in the Lancet said.
Glaxo dropped 7.8 percent. The company's Avandia diabetes pill shouldn't be prescribed for patients with some heart conditions, European regulators said on Thursday.
RSS